Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drops zap allergy itch in just minutes

NCT ID NCT05234554

Symptom relief Sponsor: Aldeyra Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an eye drop called reproxalap in 131 adults with moderate-to-severe seasonal eye allergies. Participants were exposed to ragweed pollen in a special chamber to trigger symptoms. The eye drop was compared to a placebo (no active ingredient) to see if it reduced itching and redness. Results showed reproxalap helped relieve symptoms better than the placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

131 people

The number who actually took part.

Started

Jan 2022

Finished

Apr 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be at least 18 years of age at the time of screening of either sex or any race; * Provide written informed consent; * Be willing and able to follow instructions, and can attend all required clinical trial visits. * Have at least a two-year history of moderate-to-severe ragweed-induced allergic conjunctivitis based on investigator's judgement; * Have a positive skin prick test to ragweed pollen within the past year of the Medical Screening Visit (Visit 1). Exclusion Criteria: * Have a history of blepharitis, dry eye syndrome, herpes simplex keratitis, or herpes zoster keratitis; * Have systemic signs of infection (e.g., fever, current treatment with antibiotics). * Have a systemic disease or uncontrolled medical condition, which, in the opinion of the investigator, could interfere with clinical trial measurements or subject compliance. Such diseases or conditions would include, but are not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease; * Be a WOCBP who is pregnant, nursing, or not using an effective means of contraception; * Have any known contraindication or hypersensitivities to any components of the Investigational Product (IP) drug formulation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic conjunctivitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic conjunctivitis Conjunctivitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic conjunctivitis

Contacts and locations

Locations

  • Cliantha Research

    Mississauga, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.